The pharmaceutical supply chain is built on partnerships. Pharmaceutical manufacturers rely on contract manufacturing organizations (CMOs) and contract development and manufacturing organizations (CDMOs) to support product development, production, packaging, and commercialization. Distributors, third-party logistics providers (3PLs), and other trading partners help move products through the supply chain and into the hands of customers.
While these relationships allow pharmaceutical companies to operate more efficiently, they also introduce an increasingly complex regulatory consideration: state pharmaceutical licensing responsibilities do not always begin and end with the company that owns the product or ships it to the customer.
For CMOs and CDMOs, this creates an important distinction between understanding their own licensing obligations and understanding how their activities fit into the broader pharmaceutical supply chain. The same challenge applies to manufacturers and distributors that work with multiple contract manufacturing facilities and third-party partners.
A company may have an established licensing portfolio that accurately reflects its current operations, but changes to its manufacturing arrangements, distribution network, or service offerings can introduce new licensing considerations that were never part of its original assessment.
Understanding these relationships is essential to maintaining an accurate licensing portfolio and avoiding regulatory gaps that can affect multiple organizations throughout the supply chain.
State Licensing Is Not Simply a Matter of Who Ships the Product
One of the most common misconceptions surrounding pharmaceutical licensing is that responsibility is determined primarily by which company physically ships prescription drugs into a particular state.
In reality, state licensing requirements can extend beyond the physical movement of products. Depending on the jurisdiction, the activities performed by an organization, the nature of its business, and its relationship with other companies in the supply chain may all influence whether a license is required.
For example, a CMO or CDMO may manufacture pharmaceutical products on behalf of a sponsor that ultimately distributes those products throughout the United States. Even if the manufacturing organization never directly ships products into certain states, its manufacturing activities and relationship with the sponsor may still create licensing considerations in those jurisdictions.
Similarly, a pharmaceutical manufacturer may outsource warehousing, fulfillment, or other distribution-related activities to third-party providers. Those arrangements can introduce additional licensing considerations for both the manufacturer and its service providers.
The important takeaway is that licensing assessments should consider the complete scope of an organization’s business activities and relationships, rather than relying exclusively on shipping destinations or the location of its facilities.
Understanding What Qualifies as a Third-Party Logistics Provider
Before determining which licenses and registrations may be required, a company must first understand how regulators define a third-party logistics provider.
Under the Drug Supply Chain Security Act, a 3PL is generally an entity that provides or coordinates warehousing or other logistics services for products in interstate commerce on behalf of a manufacturer, wholesale distributor, or dispenser, without taking ownership of the products or having responsibility for directing their sale or disposition.
This distinction is important because the regulatory obligations of a 3PL are not necessarily the same as those of a wholesale drug distributor.
For example, a company that provides or coordinates pharmaceutical warehousing, inventory management, and shipment services on behalf of a manufacturer or wholesale distributor, without taking ownership of the products or directing their sale or disposition, may qualify as a 3PL under the DSCSA.
In contrast, a company that takes ownership of prescription drug products and engages in their wholesale distribution may be classified as a Wholesale Drug Distributor (WDD), a separate regulatory category with its own licensing requirements. The FDA’s guidance on identifying trading partners under the DSCSA further explains the distinctions between these two types of supply chain participants.
The distinction can have significant licensing consequences.
Companies should carefully evaluate their actual business activities, contractual responsibilities, and product-handling arrangements before determining which regulatory classification applies. Simply identifying a business as a logistics provider does not automatically establish that it qualifies as a 3PL under federal or state law.
An important consideration for companies handling both pharmaceutical and medical device products: State definitions do not always mirror federal DSCSA terminology. Certain states expressly include medical devices within their 3PL licensing framework, while others may have different definitions and requirements. A company handling both product categories should evaluate its licensing obligations separately rather than assuming that a pharmaceutical 3PL license automatically covers every product or service it provides.
The Complexity of Licensing Across Multiple Business Relationships
Pharmaceutical companies rarely operate in isolation. A single product may involve a manufacturer, one or more contract manufacturing facilities, a packaging and labeling provider, a wholesale distributor, and a 3PL before reaching its final destination.
Each organization has its own operational responsibilities, and each relationship can introduce different licensing considerations.
Consider a pharmaceutical manufacturer that contracts with two CDMOs to produce different products. The manufacturer distributes those products through several wholesale distributors, each of which maintains relationships with multiple 3PLs.
From a licensing perspective, this arrangement creates several questions:
- Does each manufacturing facility maintain the licenses required for the activities it performs?
- Are the licensing obligations of the CDMOs affected by the states into which their sponsors distribute finished products?
- Do packaging, labeling, or other services introduce additional licensing considerations?
- Are the manufacturer’s wholesale distribution activities appropriately licensed?
- Do the third-party logistics providers maintain the licenses required for their specific services?
- Are all relevant state requirements being evaluated when the manufacturer adds a new trading partner or changes its distribution arrangements?
These questions illustrate why pharmaceutical licensing cannot be evaluated independently of the broader business relationship.
A manufacturer may have a well-managed licensing portfolio but still face exposure if a contract manufacturing partner or third-party provider has not adequately evaluated its own obligations. Likewise, a CMO or CDMO may be unaware that changes to a sponsor’s distribution arrangements could affect its licensing requirements.
Establishing visibility across these relationships is an important step toward preventing licensing gaps.
Defining Licensing Responsibilities Between Trading Partners
One area that deserves particular attention is the allocation of licensing responsibilities between pharmaceutical companies and their contract manufacturing and distribution partners.
Commercial agreements often establish which organization is responsible for manufacturing, quality assurance, product release, warehousing, transportation, and other operational functions. However, licensing responsibilities should receive the same level of attention.
A contract that clearly outlines operational responsibilities but leaves licensing expectations undefined can create unnecessary confusion when regulatory questions arise.
For example, a pharmaceutical sponsor may assume its CDMO is responsible for obtaining all licenses associated with its manufacturing activities. The CDMO, meanwhile, may believe it is only responsible for maintaining licenses in states where it physically ships products. If neither organization has evaluated the applicable state requirements, both may discover an issue only after a new commercial opportunity, regulatory inquiry, or internal audit.
Organizations should consider incorporating licensing responsibilities into their vendor qualification and contract management processes.
This includes establishing clear expectations regarding which party is responsible for evaluating applicable licensing requirements, maintaining licenses, monitoring expiration dates, communicating regulatory changes, and notifying the other party when operational changes may affect licensing obligations.
Importantly, contractual agreements do not replace applicable state licensing requirements or eliminate an organization’s own regulatory responsibilities. Each company must independently understand the obligations associated with the activities it performs.
Clear communication and defined responsibilities simply help ensure that important requirements are not overlooked between business partners.
Operational Changes Can Create New Licensing Obligations
Licensing portfolios are not static. As pharmaceutical companies grow, their operations evolve, and even seemingly minor business changes can warrant a new licensing assessment.
For CMOs and CDMOs, this may include adding a new manufacturing service, introducing packaging or labeling capabilities, expanding into a different product category, or entering into an agreement with a new pharmaceutical sponsor.
For manufacturers and distributors, changes may involve adding new products, engaging additional contract manufacturing facilities, expanding distribution into new states, or transitioning fulfillment activities to a different third-party provider.
Each of these developments should trigger a review of the organization’s licensing position.
Consider a pharmaceutical company that has historically worked with a single CDMO. The company decides to expand production by engaging an additional manufacturing partner with facilities in several other states. Although the company’s own distribution activities have not changed, the new manufacturing arrangement may introduce licensing questions that require evaluation.
Similarly, a CDMO that begins offering additional services to its existing customers should not automatically assume its current licensing portfolio remains sufficient. Changes in the nature or scope of its activities may affect how certain states classify its operations.
This is why licensing reviews should be integrated into broader business processes, including vendor onboarding, contract negotiations, facility expansions, service modifications, and changes to distribution networks.
Waiting until an annual licensing review to identify these developments can leave organizations with gaps that have existed for months.
Pharmaceutical and Medical Device Licensing Require Careful Distinction
Organizations operating in both the pharmaceutical and medical device industries should be particularly mindful of how licensing requirements differ between product categories and business activities.
Although pharmaceutical products and medical devices may move through many of the same manufacturing, warehousing, and distribution channels, the regulatory frameworks governing their licensing are not necessarily interchangeable.
Certain states have licensing programs that address dangerous drugs and devices within their respective regulatory frameworks, while other requirements may be specific to pharmaceutical products, particular business activities, or defined license classifications.
For organizations that manufacture, distribute, package, or provide third-party logistics services for both product categories, assuming that one licensing assessment covers everything can create unnecessary exposure.
Instead, companies should evaluate the products they handle, the activities they perform, and the specific licensing classifications applicable in each jurisdiction.
This is especially important for CMOs, CDMOs, and trading partners whose service offerings extend beyond traditional pharmaceutical manufacturing or wholesale distribution.
A comprehensive assessment should account for the full scope of operations rather than treating pharmaceutical and medical device licensing as interchangeable.
Building a Licensing Oversight Process That Keeps Pace With Operations
Managing state licenses across a complex pharmaceutical supply chain requires more than maintaining a spreadsheet of expiration dates.
Organizations need a process that connects licensing oversight to the operational information that determines where and how they conduct business.
An effective approach should include several key components.
- Maintain an accurate picture of business activities.
Document the services performed at each facility, the types of products handled, and the organization’s role in the supply chain. This information provides the foundation for determining which state licensing requirements may apply.
- Evaluate licensing requirements across all relevant jurisdictions.
Review state requirements based on the organization’s actual activities, facility locations, product classifications, and applicable business relationships. Avoid relying solely on historical licensing decisions or assumptions based on shipping destinations.
- Incorporate licensing reviews into operational changes.
New sponsors, trading partners, facilities, services, and distribution arrangements should prompt an evaluation of potential licensing implications before the changes take effect.
- Establish clear communication with trading partners.
Define licensing responsibilities and establish a process for sharing relevant updates. Changes to manufacturing arrangements, distribution territories, and service offerings should not occur without considering their potential licensing impact.
- Implement ongoing monitoring and portfolio management.
Track license expirations, renewal requirements, application statuses, state-specific obligations, and regulatory developments. Centralized oversight helps organizations identify upcoming deadlines and potential deficiencies before they become more significant problems.
- Maintain documentation of licensing decisions.
Organizations should retain records explaining how licensing requirements were evaluated, which activities were considered, and why particular licenses were obtained or determined unnecessary. This documentation can be valuable during internal audits, regulatory inquiries, sponsor due diligence, and changes in business relationships.
Together, these practices create a more reliable framework for managing licensing responsibilities across an organization’s operations and trading partner network.
Why Pharmaceutical Companies Need More Than a Reactive Licensing Strategy
The pharmaceutical supply chain continues to become more interconnected, with companies relying on increasingly complex networks of contract manufacturers, distributors, and third-party service providers.
As a result, licensing oversight can no longer be treated as an isolated administrative responsibility.
A licensing issue involving one manufacturing facility or third-party provider can create questions that affect the broader commercial relationship. It can complicate sponsor audits, delay product launches, introduce unexpected costs, and require organizations to revisit established operational arrangements.
For companies managing multiple facilities, products, sponsors, and trading partners, the challenge is not simply obtaining the licenses they need. It is maintaining an accurate understanding of how their business activities and relationships affect those requirements across all relevant jurisdictions.
The organizations best positioned to manage this complexity are those that integrate licensing oversight into their day-to-day operations rather than treating it as a task to address only when a renewal approaches or a new opportunity arises.
A More Comprehensive Approach to State Licensing
At State License Servicing, Inc. (SLS), we understand that pharmaceutical licensing extends beyond individual facilities and isolated business activities. CMOs, CDMOs, manufacturers, distributors, and other pharmaceutical organizations need a licensing strategy that accounts for the full scope of their operations.
SLS helps organizations navigate the complexities of state pharmaceutical licensing through comprehensive licensing assessments, application management, renewal tracking, and ongoing portfolio oversight.
Our team works with clients to evaluate licensing requirements, identify potential gaps, and manage the ongoing responsibilities associated with maintaining licenses across multiple states and jurisdictions.
Whether your organization operates manufacturing facilities, works with multiple contract manufacturing partners, or manages an extensive distribution network, having an experienced licensing partner can help simplify the process and provide greater visibility into your regulatory responsibilities.
Your supply chain is interconnected. Your licensing oversight should be, too.
Contact State License Servicing to learn how we can help your organization manage its state licensing portfolio and navigate the complexities of pharmaceutical and medical device licensing.